九安医疗
(002432)
| 流通市值：264.16亿 | | | 总市值：281.53亿 |
| 流通股本：4.37亿 | | | 总股本：4.66亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 531,269,303.32 | 301,482,711.39 | 1,365,588,936.68 | 1,069,311,569.11 |
| 营业收入 | 531,269,303.32 | 301,482,711.39 | 1,365,588,936.68 | 1,069,311,569.11 |
| 二、营业总成本 | 770,112,149.83 | 361,006,778.84 | 1,634,094,344.46 | 1,275,596,464.12 |
| 营业成本 | 170,653,938.79 | 93,463,056.11 | 493,971,286.09 | 369,995,524.32 |
| 税金及附加 | 2,157,690.56 | 438,649.67 | 2,648,251.55 | 1,968,240.06 |
| 销售费用 | 147,528,360.65 | 75,153,597.92 | 371,076,296.4 | 286,935,389.67 |
| 管理费用 | 194,221,596.73 | 79,629,481.64 | 474,635,281.11 | 400,638,725.18 |
| 研发费用 | 113,772,931.08 | 52,452,469.39 | 323,569,879.3 | 223,974,991.76 |
| 财务费用 | 141,777,632.01 | 59,869,524.11 | -31,806,649.99 | -7,916,406.87 |
| 其中:利息费用 | 68,243,405.17 | 29,746,463.51 | 113,523,735.72 | 87,661,109.27 |
| 其中:利息收入 | 43,125,322.53 | 23,625,138.61 | 139,086,039.26 | 109,731,439.07 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 3,647,465,375.64 | 300,155,063.44 | 2,113,542,831.27 | 1,251,365,123.94 |
| 加:投资收益 | 128,331,342.6 | 149,075,438.54 | 718,394,877.02 | 562,473,424.73 |
| 资产处置收益 | -9,258.26 | -37,605.41 | -8,487.15 | 1,044,484.58 |
| 资产减值损失(新) | -8,905,859.29 | -198,566.55 | -34,568,309.71 | -13,872,019.25 |
| 信用减值损失(新) | -3,605,576.16 | -928,430.22 | 2,763,905.92 | -2,330,146.47 |
| 其他收益 | 1,999,155.35 | 1,265,382.36 | 3,772,942.73 | 2,672,898.64 |
| 四、营业利润 | 3,526,432,333.37 | 389,807,214.71 | 2,535,392,352.3 | 1,595,068,871.16 |
| 加:营业外收入 | 1,512,621.96 | 1,357,069.58 | 6,526,135.48 | 1,874,420.48 |
| 减:营业外支出 | 5,356,853.67 | 5,303,277.87 | 14,659,638.21 | 636,145.43 |
| 五、利润总额 | 3,522,588,101.66 | 385,861,006.42 | 2,527,258,849.57 | 1,596,307,146.21 |
| 减:所得税费用 | 448,376,134.11 | 81,403,798.43 | 257,754,358.58 | 8,548,712.55 |
| 六、净利润 | 3,074,211,967.55 | 304,457,207.99 | 2,269,504,490.99 | 1,587,758,433.66 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 3,074,211,967.55 | 304,457,207.99 | 2,269,504,490.99 | 1,587,758,433.66 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 3,070,222,755.5 | 293,533,252.5 | 2,266,748,271.38 | 1,589,064,898.75 |
| 少数股东损益 | 3,989,212.05 | 10,923,955.49 | 2,756,219.61 | -1,306,465.09 |
| 扣除非经常损益后的净利润 | 3,040,332,762.15 | 345,084,121.26 | 2,292,144,672.33 | 1,577,970,459.76 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 7.33 | 0.7 | 5.23 | 3.66 |
| (二)稀释每股收益 | 7.33 | 0.7 | 5.21 | 3.64 |
| 八、其他综合收益 | -1,094,749,924.08 | -510,988,207.81 | -504,390,801.11 | 81,832,104.69 |
| 归属于母公司股东的其他综合收益 | -1,088,696,489.74 | -507,851,296.41 | -495,011,863.89 | 82,959,399.81 |
| 九、综合收益总额 | 1,979,462,043.47 | -206,530,999.82 | 1,765,113,689.88 | 1,669,590,538.35 |
| 归属于母公司股东的综合收益总额 | 1,981,526,265.76 | -214,318,043.91 | 1,771,736,407.49 | 1,672,024,298.56 |
| 归属于少数股东的综合收益总额 | -2,064,222.29 | 7,787,044.09 | -6,622,717.61 | -2,433,760.21 |
| 公告日期 | 2026-08-25 | 2026-04-29 | 2026-04-29 | 2025-10-25 |
| 审计意见(境内) | | | 标准无保留意见 | |